.png){kind=icon}
.png){kind=icon}
Return
Multiple Myeloma, Version 2.2016
.png){kind=icon}
OA
AI
DOI：10.6004/jnccn.2015.0167.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Multiple myeloma (MM) is a malignant neoplasm of plasma cells that accumulate in bone marrow, leading to bone destruction and marrow failure. Recent statistics from the American Cancer Society indicate that the incidence of MM is increasing. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) included in this issue address management of patients with solitary plasmacytoma and newly diagnosed MM. (J Natl Compr Canc Netw 2015;13:1398-1435)
Keywords:
STEM-CELL TRANSPLANTATION
THALIDOMIDE PLUS DEXAMETHASONE
HIGH-DOSE THERAPY
DONOR LYMPHOCYTE INFUSIONS
LONG-TERM SURVIVAL
NATIONAL-CANCER-INSTITUTE
SINGLE-AGENT CARFILZOMIB
NEWLY-DIAGNOSED MYELOMA
PHASE-III
INDUCTION THERAPY
Journal
J
IF:
16.4
Papers:
2.8K
Citations:
1.5W
Organization
View more organizations